Priothera SAS

Priothera is a France-based biotechnology startup founded in 2020, with a focus on improving the lives of patients suffering from hematological malignancies. The company's dedication is evident from its slogan, "Adding Quality Years of Life," and its innovative approach. Priothera's main aim is to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) by delivering an innovative immune modulator.

In April 2022, the company secured a significant €1.50M Debt Financing investment, with the support of Bpifrance. This injection of capital not only showcases the confidence that investors have in the company's mission but also provides Priothera with the resources necessary to further develop and advance its groundbreaking approach.

As a startup operating in the fields of biotechnology, healthcare, and pharmaceuticals, Priothera is positioned within highly impactful industries. With its innovative solution addressing a pressing medical need, the company has the potential to make a significant difference in the lives of patients. The recent investment represents a crucial stepping stone in Priothera's journey to revolutionize treatment options for hematological malignancies.